Lamegom

Agomelatine, the active ingredient in Lamegom, is a melatonergic agonist antidepressant presented as an oral dosage form for oral use. It works by resynchronising circadian rhythms and is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Lamegom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets. The company provides reliable sourcing, batch‑to‑batch consistency, and comprehensive documentation to meet global procurement standards. All shipments undergo rigorous quality control before release.

Agomelatine is used to treat depressive disorders by targeting circadian rhythm dysregulation.

Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. Depressive episodes with sleep disturbances: helps normalize sleep patterns and mood regulation.

Agomelatine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache occurring early in treatment. - Nausea: occasional feeling of nausea, usually transient. - Dizziness: light‑headedness or vertigo reported by some patients. - Insomnia: difficulty falling or staying asleep during initial weeks.

Serious or Rare Side Effects: - Elevated liver enzymes or hepatitis: significant increase in hepatic enzymes indicating possible liver injury. - Severe skin reactions (e.g., Stevens‑Johnson syndrome): rare but potentially life‑threatening dermatologic events. - Suicidal thoughts or behavior: emergence or worsening of suicidal ideation requiring immediate medical attention.

When prescribing agomelatine, several safety considerations should be observed.

- Liver function monitoring: assess hepatic enzymes before starting and periodically during therapy. - Avoid in severe hepatic impairment: contraindicated in patients with significant liver disease. - Caution with suicidal risk: monitor patients for emergence or worsening of suicidal thoughts. - Drug interaction caution: do not co‑administer strong CYP1A2 inhibitors such as fluvoxamine. - Alcohol consumption: limit alcohol intake as it may increase liver toxicity. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Agomelatine interacts with several medicines, requiring avoidance or careful monitoring.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, erythromycin): can markedly increase agomelatine plasma levels. - Concomitant hepatotoxic drugs (e.g., isoniazid, methotrexate): raise risk of liver injury. - Alcohol: combined use may exacerbate hepatic toxicity.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., rifampicin, smoking): may reduce agomelatine efficacy. - Other antidepressants (e.g., SSRIs, SNRIs): monitor for additive side effects. - CNS depressants (e.g., benzodiazepines): may increase sedation.